AstraZeneca — Where Your Surfaces Lose the Decision (Spring 2026)

A read on where AZ's HCP and DTC surfaces lose the prescriber or patient mid-decision — indication routing, biomarker pathways, the savings-card dead-end — with the agent opportunity mapped to each.